The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART) ; volume:13 ; number:4 ; day:8 ; month:11 ; year:2010 ; pages:1-2 ; date:12.2010
Journal of the International AIDS Society / International AIDS Society ; 13, Heft 4 (8.11.2010), 1-2, 12.2010
- Urheber
-
Cassetti, I.
- Beteiligte Personen und Organisationen
-
Etzel, A.
Madruga, JV
Suleiman, JM
Zhou, Y.
Rhee, M.
Warren, DR
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-13-S4-P86
- URN
-
urn:nbn:de:1111-2016052059025
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cassetti, I.
- Etzel, A.
- Madruga, JV
- Suleiman, JM
- Zhou, Y.
- Rhee, M.
- Warren, DR
- SpringerLink (Online service)
Ähnliche Objekte (12)
5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
Tenofovir (TDF) containing first-line HAART is associated with changes in plasma parameters suggestive of increased bone resorption
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
3OD – Once-daily (OD) TDF-containing HAART in HIV-1-infected former IVDU-patients receiving opiate substitution: efficacy, tolerability and adherence
A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
Correction to: A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
Evidence for the roles of oxidative stress, nitrosative stress and Nf-Kb activation in Tenofovir Disoproxil Fumarate (TDF) induced renal damage in rats
Chiral Analysis of the Key Intermediates of Tenofovir Alafenamide Fumarate
Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study
Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study
Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
Tenofovir (TDF) containing first-line HAART is associated with changes in plasma parameters suggestive of increased bone resorption
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
3OD – Once-daily (OD) TDF-containing HAART in HIV-1-infected former IVDU-patients receiving opiate substitution: efficacy, tolerability and adherence
A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
Correction to: A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
Evidence for the roles of oxidative stress, nitrosative stress and Nf-Kb activation in Tenofovir Disoproxil Fumarate (TDF) induced renal damage in rats
Chiral Analysis of the Key Intermediates of Tenofovir Alafenamide Fumarate
Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study
Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study
Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
Tenofovir (TDF) containing first-line HAART is associated with changes in plasma parameters suggestive of increased bone resorption
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
3OD – Once-daily (OD) TDF-containing HAART in HIV-1-infected former IVDU-patients receiving opiate substitution: efficacy, tolerability and adherence
A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
Correction to: A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
Evidence for the roles of oxidative stress, nitrosative stress and Nf-Kb activation in Tenofovir Disoproxil Fumarate (TDF) induced renal damage in rats
Chiral Analysis of the Key Intermediates of Tenofovir Alafenamide Fumarate
Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study
Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study